Cardiac stem cell therapy: Have we put too much hype in which cell type to use?
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 605479100 | ||
| 003 | CHVBK | ||
| 005 | 20210128100408.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 210128e20150901xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1007/s10741-015-9494-7 |2 doi |
| 035 | |a (NATIONALLICENCE)springer-10.1007/s10741-015-9494-7 | ||
| 245 | 0 | 0 | |a Cardiac stem cell therapy: Have we put too much hype in which cell type to use? |h [Elektronische Daten] |c [Jianqin Ye, Yerem Yeghiazarians] |
| 520 | 3 | |a Injection of various stem cells has been tested with the hopes of improving cardiac function after a myocardial infarction (MI). However, there is continued controversy as to which cell type is best for repair. Due to technical differences in cell isolation, processing, delivery, and cardiac functional assessment by various investigators, it has been difficult to directly compare the results of different cells. Using same techniques to evaluate the efficacy of different cell types, we have separately delivered bone marrow cells (BMCs), cardiospheres (CSs), CS-derived Sca-1+/CD45− cells, human embryonic stem cell-derived cardiomyocytes, and BMC extract into infarcted murine myocardium and found that all of these treatments reduce infarct size and improve cardiac function post-MI similarly without one regimen being superior to another. The beneficial effects appear to be via paracrine influences. Different progenitors lead to improved cardiac function post-MI, but it is premature to hype any specific cell type at this time. | |
| 540 | |a Springer Science+Business Media New York, 2015 | ||
| 690 | 7 | |a Cardiac progenitor cells |2 nationallicence | |
| 690 | 7 | |a Bone marrow cells |2 nationallicence | |
| 690 | 7 | |a Cardiosphere |2 nationallicence | |
| 690 | 7 | |a Human embryonic stem cells |2 nationallicence | |
| 690 | 7 | |a Cell therapy |2 nationallicence | |
| 700 | 1 | |a Ye |D Jianqin |u Division of Cardiology, Department of Medicine, University of California, 94143, San Francisco, CA, USA |4 aut | |
| 700 | 1 | |a Yeghiazarians |D Yerem |u Division of Cardiology, Department of Medicine, University of California, 94143, San Francisco, CA, USA |4 aut | |
| 773 | 0 | |t Heart Failure Reviews |d Springer US; http://www.springer-ny.com |g 20/5(2015-09-01), 613-619 |x 1382-4147 |q 20:5<613 |1 2015 |2 20 |o 10741 | |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s10741-015-9494-7 |q text/html |z Onlinezugriff via DOI |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 900 | 7 | |a Metadata rights reserved |b Springer special CC-BY-NC licence |2 nationallicence | |
| 908 | |D 1 |a research-article |2 jats | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-springer | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1007/s10741-015-9494-7 |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Ye |D Jianqin |u Division of Cardiology, Department of Medicine, University of California, 94143, San Francisco, CA, USA |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Yeghiazarians |D Yerem |u Division of Cardiology, Department of Medicine, University of California, 94143, San Francisco, CA, USA |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t Heart Failure Reviews |d Springer US; http://www.springer-ny.com |g 20/5(2015-09-01), 613-619 |x 1382-4147 |q 20:5<613 |1 2015 |2 20 |o 10741 | ||